Alnylam Pharmaceuticalsvs.Regeneron
ALNY vs REGN · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Regeneron is about 2.5× larger than Alnylam Pharmaceuticals by market cap; Regeneron trades at the lower P/E (17.6 vs 37.2); year to date, Regeneron leads (−4.2% vs −43.5%).
Side by side
| ALNY | REGN | |
|---|---|---|
| Market cap | $30B | $76.1B |
| Price | $232.68 | $746.54 |
| Today | +3.6% | +0.9% |
| Return YTD | −43.5% | −4.2% |
| Return 1Y | −50.2% | +31.2% |
| Since June 26, 2026 | −20.1% | +18.0% |
| P/E | 37.2 | 17.6 |
| P/S | 6.3 | 4.9 |
| P/B | 22.2 | 2.4 |
Data as of 2026-10-09 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
Alnylam PharmaceuticalsALNY
Turns RNA interference into drugs, mostly for rare and cardiovascular disease.
Full ALNY profile →RegeneronREGN
Antibody engineering underpins the whole portfolio, from Eylea in ophthalmology to Dupixent, partnered with Sanofi, in immunology. Oncology is the newer front.
Full REGN profile →More ALNY & REGN comparisons
Other head-to-heads in the Biotech & innovation segment.